

Dear Editor,

We are glad that we have this opportunity and that you are considering our manuscript to be published in the *World Journal of Diabetes*. We are especially thankful for this revision process and all suggestions that have greatly improved our manuscript.

Answers to all reviewer's comments were made point by point and marked yellow in the text. Some references were added and marked in the text.

Reviewer #1

1. The authors should consider identifying the manuscript as a review in the title.

We have now identified the manuscript as a minireview in the title per the reviewer's recommendation.

2. In the chapter "Galectin-3 and neuro-immuno-metabolic crosstalk" the name of the first author of the reference 57 is misspelled (line 177).

We have now corrected the name of the first author of reference 57 (now this reference is number 58) in the chapter "Galectin-3 and neuro-immuno-metabolic crosstalk".

3. Please consider changing "triglyceride" to "triglycerides" (line 183).

We have changed "triglyceride" to "triglycerides" (line 183).

4. In my opinion, it would be better to say that antipsychotics might cause weight gain, glucose intolerance and other metabolic complications (lines 198-199).

This sentence is now revised per the reviewer's recommendation.

Reviewer #2

1. I believe the paper can be improved if the authors designed some interesting original Figures and (or) Table to summarize their findings. You can use PowerPoint to prepare some simple figures as it would increase the readability of your paper and attract more readers (and subsequently citations).

In attempt to summarize our findings we have now designed and added the figure to the manuscript.

2. Chronic comorbidities, e.g., obesity, diabetes, diabetes, hypertension etc., are also characterized by high oxidative stress and low-grade chronic inflammation levels. The authors should acknowledge the fact that patients with schizophrenia most probably have other comorbidities as well and these might also lead to metabolic alterations. If you are interested to read more about the involvement of oxidative stress in diabetes, diabetes, obesity, diabetic dyslipidemia etc, there are some interesting articles previously published in World Journal of Diabetes that you can search for.

In the Introduction, we have now acknowledged the fact that the patients with schizophrenia most probably have other comorbidities as well and these might also lead to metabolic alterations and rearrange the order of the sentences and references in the first paragraph.

In the first paragraph of the section about Galectin-3 and neuro-immuno-metabolic crosstalk, we have now added the fact that oxidative stress is involved in neurodegenerative and metabolic disorders and substantiated this with reference.

3. How are galectin-3 levels influenced by the previously mentioned comorbidities? Or what other factors can influence its levels?

In the second paragraph of the section about Galectin-3 and neuro-immuno-metabolic crosstalk, we have now added the factors that can influence Galectin-3 levels in diverse comorbidities.

Other specific requirements

1. *Title: Please spell out any abbreviation in the title. Abbreviations are not permitted.*

We do not have abbreviations in the title.

2. *Running title: Please shorten the running title to no more than 6 words. Abbreviations are permitted.*

We have now provided a running title.

3. *Abstract: Abbreviations must be defined upon the first appearance in the Abstract.*

We have defined abbreviations upon the first appearance in the Abstract.

4. *Key words: Abbreviations must be defined upon the first appearance in the Key words.*

We have defined abbreviations upon the first appearance in the Key words.

5. *Core tip: Abbreviations must be defined upon the first appearance in the Core tip.*

We have defined abbreviations upon the first appearance in the Core tip.

6. *Main Text: Abbreviations must be defined upon the first appearance in the Main Text.*

We have defined abbreviations upon the first appearance in the Main text.

7. *Article Highlights: Abbreviations must be defined upon first appearance in the Article Highlights.*

We do not have article highlights because our manuscript is minireview.

8. *Figures: Please verify the abbreviations used in figures and define them (separated by semicolons) at the end of the figure legend or table.*

We have verified the abbreviations used in figures and defined them at the end of the figure legend.

Editorial Office's comments

1. *Science editor*

Conditional acceptance after minor revision.

Thank you for your revision.

2. *Company editor-in-chief*

Before final acceptance, the author(s) must add a table/figure to the manuscript.

We have now added the figure to the manuscript.